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We conducted a retrospective cross-sectional study to estimate the humanistic and economic burden associated with depression
and anxiety among adults with comorbid diabetes and hypertension. Pooled data from the 2013 and 2015 Medical Expenditure
Panel Survey were used to include adults (≥18 years old) who were alive and diagnosed with both diabetes and hypertension
during the observation period. We assessed the humanistic burden with health-related quality of life (HRQoL) and economic
burden with the total annual healthcare expenditures. Depending on the presence/absence of depression and anxiety, the study
sample was divided into four groups (i.e., no depression/anxiety, depression only, anxiety only, and depression and anxiety).
Multivariable regression analyses were used to evaluate the associations between the depression/anxiety categories and disease
burden measures. The incremental burden associated with depression and/or anxiety was estimated with the counterfactual
recycled prediction. Of the 4560 adults with comorbid diabetes and hypertension, 13.2% reported depression only, 8.7%
reported anxiety only, and 7.7% reported both. Results from adjusted analyses indicated that the presence/absence of depression
and anxiety was associated with significantly poorer HRQoL, especially on the mental component. Having either depression or
anxiety corresponded to reduced mental component summary scores by more than four points. The reduction was as high as
10.35 points when both conditions occurred. Comparing to adults without depression or anxiety, the per-capital incremental
annual healthcare expenditures were $4607 for the depression group, $2481 for the anxiety group, and $8709 for adults with
both conditions. Furthermore, adults with depression and anxiety were 58% more likely to spend at least 10% of annual
household income on healthcare as compared to those with neither the conditions. Our results highlight the needs for
integrating cost-effective mental health services into diabetes management to improve the HRQoL and reduce healthcare costs
for adults with comorbid diabetes and hypertension.
1. Introduction
Comorbid chronic conditions can post an enormous
challenge in diabetes care. Hypertension is one of the most
common comorbid conditions due to a considerable overlap
of risk factors [1]. Approximately 75% of individuals diag-
nosed with diabetes have concomitant hypertension, repre-
senting nearly 23 million adults in the United States (US)
[1, 2]. Individuals with multiple chronic conditions usually
have impaired mental health [3]. Like many other chronic
conditions, diabetes and hypertension are independently
associated with a higher prevalence of mental conditions,
particularly depression and anxiety [4]. The prevalence of
depression and anxiety ranges from 15% to 35% among
individuals with diabetes [5, 6] and 22% to 56% among those
with hypertension [7, 8].
The presence of depression and/or anxiety can impose
substantial disease burdens on adults with comorbid diabetes
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and hypertension as they ranked amongst the top ten causes
of disease burden in the 2013 Global Burden of Disease Study
[9]. The presence of either the condition can complicate the
course of diabetes and hypertension by causing increased
inflammation, unhealthy lifestyles, and poor adherence to
treatments [10]. Furthermore, depression and anxiety can
lead to significant functional impairments, resulting in poor
quality of life [11, 12]. Results from several observational
studies have indicated that depression and anxiety manifest
themselves in multiple facets of the quality of life for individ-
uals with diabetes, including functional, cognitive, and emo-
tional domains [13–15].
The impairment in quality of life also represents a consid-
erable economic burden on patients, their family members,
and the whole healthcare system due to high use of health-
care services. Diabetes is one of the most expensive chronic
conditions in the US, with an estimated medical expenditure
of $237 billion in 2017 [16]. Based on the finding of a recent
study, the national burden of comorbid diabetes and hyper-
tension could exceed $350 billion [17]. Depression and
anxiety have been indicated with higher risks of diabetes
complications and heart diseases, leading to excess costs from
more physician office visits, emergency room or inpatient
admissions, and prescription consumption [18, 19].
Depression, anxiety, diabetes, and hypertension are
closely linked and affect a substantial proportion of the US
population. Individuals that carry more than one, or even
all four conditions, face unique challenges regarding access
to the healthcare resources and the emotional state to achieve
optimal treatment goals. Evaluating the burden of mental
comorbidities has indispensable roles in achieving these
goals because it helps direct resource allocation for policy-
makers. Like diabetes and hypertension, depression and
anxiety also have substantial overlap in occurrence [20].
Although previous studies have evaluated the impact of
depression and anxiety on individuals with diabetes or
hypertension separately, no study has comprehensively
quantified the effect of either of the condition alone. Fur-
thermore, researchers have reported that treating comor-
bid depression and anxiety could be more challenging
than managing each condition alone [21]. Research atten-
tion on comorbid depression and anxiety is therefore war-
ranted to help understand the unmet needs in providing
care to patients with such complex conditions. Therefore,
the objective of this study is to estimate the humanistic
and economic burden of depression and/or anxiety among
adults with comorbid diabetes and hypertension.
2. Materials and Methods
2.1. Study Design. This study utilized a retrospective cross-
sectional design.
2.2. Data Source. We pooled data from the 2013 and 2015
Medical Expenditure Panel Survey (MEPS). The MEPS is a
nationally representative survey of noninstitutionalized
adults. It collects information on demographics and various
facets of healthcare, including medical conditions, access to
care, health-related quality of life (HRQoL), and medical
expenditures. The MEPS employs a panel design, in which
participants were followed for two years. As recommended
byMEPS, we utilized alternate years to avoid duplicate obser-
vations of the same participant [22].
2.3. Study Sample. Our descriptive sample consisted of 4560
adults (aged 18 or older) who were alive and diagnosed with
both diabetes and hypertension during the study period
(2013 and 2015). Diabetes and hypertension were identified
from the full-year consolidated file based on queries
regarding the diagnosis of specific conditions or medical
condition files using the clinical classification codes (49–50
for diabetes, 98–99 for hypertension). These conditions
were reported by households, recorded by professional
coders, and then converted into clinical classification codes
by MEPS researchers. Because the MEPS only collects data
on HRQoL through self-administered questionnaires
(SAQ), we further restricted our sample to adults who were
eligible for SAQ to analyze humanistic outcomes. For eco-
nomic outcomes, the analytic cohort only included adults
with positive expenditures.
2.4. Dependent Variables
2.4.1. Humanistic Outcome: Health-Related Quality of Life
(HRQoL). MEPS measures HRQoL with the 12-item short-
form health survey version 2 (SF-12v2). The SF-12v2 is a
widely used generic measure for HRQoL in health services
research. MEPS researchers combined, scored, and weighted
the responses to create physical component summary (PCS)
and mental component summary (MCS) scores. The scores
range from 0 to 100, with higher scores indicating better
HRQoL related to physical and/or mental health [23].
2.4.2. Economic Outcomes: Total Annual Healthcare
Expenditures. The MEPS is considered as the most complete
source of data on healthcare expenditures. Healthcare expen-
ditures are measured as any payment to healthcare providers
(i.e., hospitals, outpatient facilities, private practices, and
long-term care facilities) for healthcare services (i.e., inpa-
tient, outpatient, prescription, dental, vision, and home
health services). Payers include patients or their families
paying for a service out-of-pocket as well as third-party
payers (Medicare, Medicaid, private insurance, Veterans
Administration, Tricare, HMOs, etc.). Total annual per-
person healthcare expenditures were calculated as the sum
of all medical payments from all payers. We conducted sepa-
rate analyses on total expenditures, those paid by third parties
and out-of-pocket (OOP) spending from patients. Third-
party expenditures were calculated as the difference between
total expenditures and OOP spending. All expenditures were
adjusted to 2015 US dollars using the consumer price index
for medical services from the Bureau of Labor Statistics.
2.4.3. Economic Outcomes: OOP Spending Burden. The
economic burden from OOP spending was measured as the
percentage of annual household income spent on healthcare
as OOP payments [24]. We used a conventional cut-off of
10% to define high burden [25].
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2.5. Key Independent Variable
2.5.1. Depression/Anxiety Categories. We identified depres-
sion and anxiety from the medical condition files using the
clinical classification code of “657” and “651.”A variable with
four categories (depression and anxiety, depression only,
anxiety only, and no depression/anxiety) was created based
on the presence/absence of depression and anxiety.
2.6. Other Independent Variables.We selected other indepen-
dent variables under the guidance of the Andersen’s behav-
ioral model [26], in which an individual’s use of healthcare
services and associated outcomes is considered as a function
of predisposing factors, enabling factors, need factors,
personal health practices, and external environment. We
included sex (male/female), race/ethnicity (Whites/African-
American/Latino/other racial minorities), and age (18–39/
40–54/55–64/65–74/75+) as predisposing factors. Enabling
factors were comprised of marital status (married/not
married), education (less than high school/high school/more
than high school), family poverty status (poor/near poor/
middle income/high income), health insurance (private/pub-
lic/uninsured), and prescription insurance status (yes/no).
Need factors included having a chronic condition (yes/no)
other than diabetes and hypertension from a list of eight con-
ditions (asthma, arthritis, cancer, chronic obstructive pulmo-
nary disease, heart disease, and stroke), perceived physical
and mental health status (excellent/very good, good, and
fair/poor), and pain interference (mild/no, moderate, and a
lot/extreme). Personal health practice factors included
obesity (yes/no), smoking status (current smoker/others),
and physical activities (five times or more/week, less than five
times/week). We also used geographic region (northeast/
midwest/south/west) of residency to account for variations
due to the external environment.
2.7. Statistical Analyses. We used chi-square tests to deter-
mine statistically significant differences across study groups
for categorical variables and Student’s independent t-tests
for continuous variables. Multivariable regression analyses
were used to examine the association between the depres-
sion/anxiety categories and disease burden measures. Ordi-
nary least square regressions were employed to analyze
MCS and PCS scores. Logistic regressions were used for
binary outcomes such as OOP spending burden. To over-
come common challenges associated with modeling expendi-
tures (e.g., high positive skewness and heteroscedasticity), we
used generalized linear models with a log link function and
gamma family distribution for expenditure outcomes [27].
To estimate excess healthcare expenditures contributed
by depression and/or anxiety, we utilized counterfactual
recycled prediction. This technique is preferable because, by
creating counterfactual scenarios, it allows for adjustment
for differences in characteristics across all groups (i.e.,
depression and anxiety, depression only, anxiety only, and
neither depression nor anxiety) [28]. To account for the
complex survey design of the MEPS, we utilized the survey
procedures in the statistical analysis software (SAS) version
9.4 (Cary, NC, USA) and STATA 14. As recommended by
MEPS researchers, we computed annualized weights by
dividing personal weights by the number of years pooled
(two, in our study) [29]. Annualized SAQ weights were used
for analyzing MCS and PCS.
3. Results
3.1. Description of Study Sample. The study sample was
almost evenly female (50.1%) and male (49.9%). The major-
ity were white (62%), aged greater than 55 (76%), with multi-
morbidity (73%), and adults who had at least a high school
education (80%). Twenty-seven percent of individuals
considered themselves as having excellent or very good
physical health while 48% reported having excellent or very
good mental health (Table 1).
Within our sample, approximately one-fifth had either
depression (13.2%) or anxiety (8.7%), and 7.7% had both
conditions. We observed significant differences in the preva-
lence of depression and/or anxiety across all predisposing
factors, enabling factors, need factors, personal health
practices, and external environment with the exception for
education. For example, females with comorbid diabetes
and hypertension reported a significantly higher rate of
depression and anxiety, either alone or together, as com-
pared to their male counterparts. Similar patterns were
observed for adults with public insurances relative to private
insurances or no insurance, adults reporting multimorbidity
in addition to diabetes and hypertension versus those with-
out additional chronic conditions, and adults with severe
pain interference as compared to those with mild or no pain
interference (Table 1).
3.2. Humanistic Outcomes: Physical and Mental Component
Summary Scores (PCS and MCS). Adults with depression
and/or anxiety reported significant lower health scores, both
physically and mentally, as compared to those with neither
the condition. Across the four groups, adults with both
depression and anxiety reported the lowest MCS scores while
those with depression had the lowest PCS scores (Table 1).
However, after adjusting for all other covariates, we only
observed significant differences in MCS scores. Results from
adjusted analyses indicated that, compared to adults with
neither depression nor anxiety, the MCS scores were 10.35
points lower for those with depression and anxiety and 7.67
and 4.88 points lower for those with either depression or
anxiety, respectively (Table 2).
3.3. Economic Outcomes: Total Annual Healthcare
Expenditures. Adults with depression and/or anxiety also
had significantly higher annual healthcare expenditures than
those with neither the condition (Table 3). Adults with
depression and anxiety had the highest expenditures at
$28,832 per person per year, followed by those with either
depression ($19,648) or anxiety ($16,990). After adjusting
for all other factors that may influence healthcare expendi-
tures, results from recycled predictions showed that the
annual per-person mean healthcare expenditures were
$20,963 (95% confidence interval (CI): $20,581–$21,329)
for those with both depression and anxiety and $16,861
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Table 1: Description of study sample by depression and anxiety categories among adults with comorbid diabetes and hypertension, using










N Wt% N Wt row% N Wt row% N Wt row% N Wt row% p value sig
All 4560 100.0 309 7.7 561 13.2 366 8.7 3324 70.4
Predisposing factors
Sex <0.001 ∗∗∗
Female 2477 50.1 227 10.9 368 16.5 227 10.3 1655 62.3
Male 2083 49.9 82 4.4 193 10.0 139 7.0 1669 78.6
Race/ethnicity <0.001 ∗∗∗
White 1658 61.6 163 9.2 237 14.6 173 10.4 1085 65.8
African-American 1267 16.1 51 4.0 140 11.1 90 6.3 986 78.6
Latino 1210 14.4 80 6.8 156 13.2 87 6.4 887 73.6
Others 425 7.9 15 4.5 28 6.9 16 4.2 366 84.4
Age groups <0.001 ∗∗∗
18–39 years 224 4.4 21 10.5 30 15.5 23 8.7 150 65.3
40–54 years 1016 19.9 96 10.3 121 13.2 77 8.3 722 68.1
55–64 years 1304 26.8 98 8.6 191 16.0 98 8.8 917 66.6
65–74 years 1165 28.6 65 7.3 152 13.8 92 8.2 856 70.8
75 years or older 851 20.3 29 3.7 67 8.4 76 9.4 679 78.5
Enabling factors
Marital status <0.001 ∗∗∗
Married 2352 57.5 110 5.7 265 12.9 170 8.0 1807 73.3
Not married 2208 42.5 199 10.3 296 13.6 196 9.5 1517 66.6
Education level† 0.186
<High school 1301 19.1 74 6.0 158 11.4 106 9.3 963 73.3
High school 1447 34.2 110 8.9 174 12.9 126 9.2 1037 69.0
>HS 1751 46.7 121 7.5 223 14.2 131 8.1 1276 70.2
Poverty status‡ <0.001 ∗∗∗
Poor 1014 13.5 100 11.5 165 15.6 95 9.6 654 63.2
Near poor 1174 22.7 88 9.4 138 13.2 105 10.3 843 67.1
Middle income 1321 30.5 77 7.6 152 13.7 92 7.0 1000 71.6
High income 1051 33.3 44 5.0 106 11.8 74 8.6 827 74.6
Insurance coverage <0.001 ∗∗∗
Private 2119 57.0 100 5.8 230 13.2 161 8.3 1628 72.7
Public 2067 37.3 193 10.8 294 14.0 190 9.8 1390 65.4
Uninsured 374 5.7 16 6.1 37 9.1 15 4.6 306 80.1
Prescription insurance 0.020 ∗
Yes 1670 44.7 79 5.9 182 13.8 128 8.6 1281 71.7
No 2890 55.3 230 9.1 379 12.8 238 8.7 2043 69.4
Need factors
Perceived physical health <0.001 ∗∗∗
Excellent/very good 1037 26.7 36 4.3 85 9.2 69 8.0 847 78.5
Good 1642 38.2 81 6.1 160 11.3 117 8.1 1284 74.6
Fair/poor 1881 35.1 192 11.9 316 18.4 180 9.8 1193 59.8
Perceived mental health <0.001 ∗∗∗
Excellent/very good 1979 48.2 56 3.8 135 8.0 124 7.6 1664 80.6
Good 1702 35.8 103 7.3 228 15.3 134 8.7 1237 68.6
Fair/poor 879 16.0 150 20.1 198 24.5 108 11.6 423 43.8
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(95% CI: $16,533–$17,155) and $14,735 (95% CI:
$14,466–$14,992) for those with either depression or anxiety.
The expenditures in these three groups were all significantly
higher than the group with neither condition, with an incre-
mental expenditure of $8709 (95% CI: $8550–$8861), $4607
(95% CI: $4523–$4687), and $2481 (95% CI: $2436–$2525),
respectively (Table 3).
Similar results were found for analyses on third-party
expenditures and out-of-pocket (OOP) spending (Table 3).
For instance, third-party payers spent an excess of $9132
(95% CI: $8956–$9304) annually among adults with both
depression and anxiety than those with neither condition.
Furthermore, the former group also had $399 (95% CI:
$393–$406) more OOP spending than the latter group.
3.4. Economic Outcomes: OOP Spending Burden. We found
significantly higher percentages of adults with depression
and/or anxiety bearing a high OOP spending burden (i.e.,
spending 10% or more of income on healthcare) than those
without these two conditions (Table 4). Specifically, approx-
imately one-third (34.0%) of those with both depression and
anxiety had high OOP burden versus 18.3% of those with
neither the conditions. Results from unadjusted and adjusted
logistic regressions consistently indicated that adults having
depression and anxiety were more likely to suffer from high
OOP burden as compared to those with neither the condi-
tions. However, we did not observe any significant associa-
tion between either condition alone (depression or anxiety)
and high OOP burden after adjusting for all the predisposing
factors, enabling factors, need factors, personal health prac-
tices, and external environment (Table 4).
4. Discussion
This study comprehensively evaluated the humanistic and
economic burden associated with depression and anxiety,
alone and together, among a nationally representative sample











N Wt% N Wt row% N Wt row% N Wt row% N Wt row% p value sig
Multimorbidity <0.001 ∗∗∗
Yes 3179 72.6 198 8.6 369 15.3 212 8.8 1729 67.3
No 1381 27.4 104 6.3 180 10.4 146 8.3 1525 75.0
Pain interference <0.001 ∗∗∗
None/little 2240 50.5 95 5.5 191 9.7 143 7.6 1811 77.3
Moderate 757 17.5 58 8.4 103 14.4 64 8.6 532 68.6
A lot/extreme 1204 25.0 136 12.1 228 20.2 132 11.2 708 56.6
Not reported 359 7.1 20 5.9 39 11.3 27 7.5 273 75.3
Personal health practice
Obesity†, ⁋ <0.001 ∗∗∗
Yes 2508 57.3 198 8.6 369 15.3 212 8.8 1729 67.3
No 1955 42.7 104 6.3 180 10.4 146 8.3 1525 75.0
Current smoker <0.001 ∗∗∗
Yes 578 12.2 77 12.8 103 21.0 49 7.7 349 58.5
No 3553 79.2 214 7.1 415 12.4 281 8.7 2643 71.7
Not reported 429 8.6 18 5.5 43 9.7 36 9.1 332 75.7
Exercise≥ 5 times/week† <0.001 ∗∗∗
Yes 1584 34.7 77 6.1 154 10.1 99 6.6 1254 77.2
No 2938 65.3 229 8.5 402 14.9 266 9.8 2041 66.8
External environment
Region 0.027 ∗
Northeast 740 17.2 76 11.1 99 12.7 56 8.1 509 68.0
Midwest 800 22.0 69 8.9 106 13.0 80 10.2 545 67.9
South 2011 42.6 109 5.7 250 13.9 166 8.7 1486 71.7
West 1009 18.3 55 7.6 106 12.4 64 7.2 784 72.8
Note: study sample included adults (≥18 years old) with comorbid diabetes and hypertension who were alive in the observation year (2013/2015). Wt%:
weighted percentages; Wt row%: weighted row percentages; Sig.: statistical significance level. †Some groups with missing data were not reported here due to
small cell size (<10). ‡Poverty status was calculated from the annual family income and family composition using the federal poverty line (FPL). Poor was
defined as <100% FPL; near poor was defined as >100% FPL and <199% FPL; middle income was defined as >200% FPL and <399% FPL; high income was
defined as >400% FPL. ⁋Obesity was defined as body mass index ≥ 30.0. ∗p < 0 05; ∗∗0 001 < p < 0 01; ∗∗∗p < 0 001.
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results revealed that a substantial proportion of adults with
comorbid diabetes and hypertension suffered from depres-
sion and/or anxiety. Some subgroups such as females, indi-
viduals with low socioeconomic status, current smokers,
and those with severe pain were more vulnerable than others
to be affected. Adding regular check-ups for mental health to
diabetes management for these subgroups may help prevent
the development of depression or anxiety.
Our study findings showed that depression and anxiety,
either alone or together, were associated with poorer quality
of life relative to mental health, but not physical health,
among adults with comorbid diabetes and hypertension. It
is expected that individuals with mental health diagnoses
perceived poorer mental health. Although previous literature
suggested that depression could impact physical health [30],
we did not observe such association after adjusting for all
the predisposing factors, enabling factors, need factors,
personal health practice, and the external environment.
We speculated that adults with diabetes and hypertension
perceived the role limitations and impaired functional status
affected by emotional problems rather than physical
sufferings. It is also possible that they received more medical
attention to physical symptoms than mental problems from
healthcare providers. Results from the National Comor-
bidity Survey Replication indicated that 60% of adults
with a recent mental health condition did not receive care
from healthcare professional [31]. Removing barriers to
seeking mental healthcare (i.e., mental health stigma)
and increasing access to mental health services are pivotal
to improve the quality of life for patients with comorbid
diabetes and hypertension.
In addition to impairments in quality of life, adults with
comorbid diabetes and hypertension also born excess eco-
nomic burden from depression and anxiety, especially when
both conditions occurred. Li and colleagues reported that
almost one-fourth of adults with diabetes spent considerable
proportion (>10%) of family income for healthcare [32]. The
presence of comorbid depression and anxiety may expose
more diabetes patients and their families to financial difficul-
ties. Such excess spending burden may come from paying for
behavioral health interventions, which have relatively low
reimbursement rates. Lifting restrictions and increasing
reimbursement rates for behavioral health services can
enable more diabetes patients to afford the care needed for
their overall well-being. Not only patients but also healthcare
payers such as Medicare, Medicaid, and private insurance
companies have significantly higher costs due to depression,
anxiety, and the combination of these two. We estimated that
depression and anxiety together accounted for an excess
of $14.3 billion medical expenditures (2015 USD) for
third-party payers annually. The new payment model for
behavioral health services implemented by the Centers
for Medicare and Medicaid Services may be promising
in reducing costs for both patients and payers [33].
Like any other research study, our findings should be
interpreted along with the study strengths and limitations.
We believe this to be the first study that comprehensively
examined the humanistic and economic burden of depres-
sion and anxiety among adults with comorbid diabetes and
hypertension in a nationally representative sample. Also,
our study utilized data that allows for adjustment of a com-
prehensive list of confounders. The recycled predictions
Table 2: Unadjusted and adjusted coefficients for depression and anxiety categories from ordinary least square (OLS) regressions on physical
component summary (PCS) and mental component summary (MCS) scores among adults with comorbid diabetes and hypertension, using
pooled data from the 2013 and 2015 Medical Expenditure Panel Survey (MEPS).
Unadjusted means and SE
PCS MCS
Mean (SE) p value Mean (SE) p value
Depression and anxiety 37.27 (0.96) ∗∗∗ <0.001 40.45 (0.94) ∗∗∗ <0.001
Depression only 37.02 (0.97) ∗∗∗ <0.001 43.76 (0.71) ∗∗∗ <0.001
Anxiety only 38.38 (1.04) ∗ 0.016 46.96 (0.78) ∗∗∗ <0.001
No depression/anxiety (reference group) 40.92 (0.34) 52.8 (0.23)
Parameter estimates and SE from multivariable OLS regressions†
PCS MCS
Beta (SE) p value Beta (SE) p value
Depression and anxiety −0.68 (0.87) 0.432 −10.35 (0.91) ∗∗∗ <0.001
Depression only −1.37 (0.83) 0.098 −7.67 (0.66) ∗∗∗ <0.001
Anxiety only 0.01 (0.80) 0.987 −4.88 (0.74) ∗∗∗ <0.001
No depression/anxiety (reference group)
Note: the analytic sample consisted of adults (>18 years) with comorbid diabetes and hypertension who were alive and eligible for the self-administered
questionnaires of MEPS in the observation year (2013/2015). SE: standard error of the mean; Beta: parameter estimates from multivariable OLS regressions.
†Covariates included in the multivariable OLS regressions included predisposing factors (sex, age groups, and race/ethnicity), enabling factors (marital
status, education level, poverty status, health insurance coverage, and prescription drug insurance coverage), enabling factor (presence/absence of other
chronic conditions, pain interference), personal health practice (obesity, smoking status, and exercise level), and external environment (region). Pain
interference was not included in the regression on PCS scores because it was used in the computation of PCS scores with heavy weights. ∗p < 0 05;
∗∗p < 0 01; ∗∗∗p < 0 001.
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Table 4: Unadjusted and adjusted association between depression and anxiety categories and high out-of-pocket (OOP) spending burden
among adults with comorbid diabetes and hypertension, using pooled data from the 2013 and 2015 Medical Expenditure Panel Survey.
Bivariate association between depression and anxiety categories and high OOP spending burden
High burden† Not high burden
N Wt row% N Wt row% p value Sig.
Depression and anxiety 90 34.0 219 66.0 <0.001 ∗∗∗
Depression only 158 28.2 403 71.8
Anxiety only 96 23.5 270 76.5
No depression/anxiety 650 18.3 2674 81.7
Logistic regressions on high OOP spending burden†
Unadjusted model Adjusted model‡
OR 95% CI Sig. AOR 95% CI Sig.
Depression and anxiety 2.26 (1.66–3.07) ∗∗∗ 1.55 (1.06–2.25) ∗
Depression only 1.72 (1.28–2.32) ∗∗∗ 1.25 (0.91–1.70)
Anxiety only 1.34 (1.04–1.74) ∗ 1.03 (0.77–1.38)
No depression/anxiety (reference group)
Note: the analytic sample consisted of adults (>18 years) with comorbid diabetes and hypertension who were alive and had positive expenditures in the
observation year (2013/2015). Wt row%: weighted row percentages; Sig.: statistical significance level; OR: odds ratio; AOR: adjusted odds ratio; 95% CI: 95%
confidence interval. †OOP spending burden was measured by the percentage of household income spent on healthcare. It was calculated by dividing OOP
spending by household income. High OOP spending burden was defined as 10% or more. ‡Covariates adjusted in the logistic regression included
predisposing factors (sex, age groups, and race/ethnicity), enabling factors (marital status, education level, poverty status, health insurance coverage, and
prescription drug insurance coverage), enabling factor (presence/absence of other chronic conditions, pain interference), personal health practice (obesity,
smoking status, and exercise level), and external environment (region). ∗p < 0 05; ∗∗p < 0 01; ∗∗∗p < 0 001.
Table 3: Unadjusted and adjusted annual per-person mean healthcare expenditures (2015 US$) by depression and anxiety categories among
adults with comorbid diabetes and hypertension, using pooled data from the 2013 and 2015 Medical Expenditure Panel Survey.
N








Depression and anxiety 309 28,832.15 (5963.66) ∗∗ 20,962.68 (20,580.69–21,328.80) 8708.81 (8550.11–8860.90)
Depression only 559 19,648.34 (1,542.8) ∗∗∗ 16,860.66 (16,553.42–17,155.13) 4606.78 (4522.84–4687.24)
Anxiety only 366 16,990.31 (2008.43) ∗∗ 14,735.14 (14,466.63–14,992.49) 2481.26 (2436.05–2524.60)
No depression/anxiety 3256 11,543.4 (448.52) 12,253.88 (12,030.58–12,467.89) (reference group)
Third-party payers
Depression and anxiety 309 27,009.6 (5928.43) ∗∗ 20,396.77 (20,003.49–20,782.35) 9132.19 (8956.11–9304.83)
Depression only 559 17,844.71 (1436.02) ∗∗∗ 15,659.59 (15,357.65–15,955.62) 4395.01 (4310.27–4478.09)
Anxiety only 366 15,236.58 (1996.7) ∗ 13,273.26 (13,017.34–13,524.18) 2008.69 (1969.96–2046.66)
No depression/anxiety 3256 10,420.07 (445.14) 11,264.58 (11,047.38–11,477.53) (reference group)
Out-of-pocket
Depression and anxiety 309 1822.54 (207.53) ∗∗∗ 1382.75 (1361.19–1405.12) 399.31 (393.08–405.77)
Depression only 559 1803.64 (236.02) ∗∗ 1364.25 (1342.98–1386.32) 380.81 (374.88–386.98)
Anxiety only 366 1753.73 (231.31) ∗∗ 1312.70 (1292.23–1333.94) 329.26 (324.12–334.59)
No depression/anxiety 3256 1123.33 (41.17) 983.44 (968.10–999.35) (reference group)
Note: the analytic sample consisted of adults (>18 years) with comorbid diabetes and hypertension who were alive and had positive expenditures in the
observation year (2013/2015). All the expenditures were converted to 2015 US dollars using the consumer product index from the US Bureau of Labor
Statistics. SE: standard error of the mean. †The adjusted annual per-person mean/incremental healthcare expenditures were obtained from recycled
predictions based on the estimates of generalized linear model (GLM) with log link function and gamma distribution. Covariates adjusted in the GLM
included predisposing factors (sex, age groups, and race/ethnicity), enabling factors (marital status, education level, poverty status, health insurance
coverage, and prescription drug insurance coverage), enabling factor (presence/absence of other chronic conditions, pain interference), personal health
practice (obesity, smoking status, and exercise level), and external environment (region). ‡Confidence intervals are based on 2000 bootstrap replications
using the percentile method. ∗p < 0 05; ∗∗p < 0 01; ∗∗∗p < 0 001.
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provide realistic estimates of healthcare expenditures for a
typical diabetes patient. Such estimates can be better compre-
hended by policymakers than parameter estimates from con-
ventional regression analyses. However, there are limitations
as well. First, the study results may subject to recall and social
desirability bias due to the self-reported nature of the MEPS
data. Second, there might be misclassification bias from
undiagnosed depression/anxiety, leading to underestimation
of the disease burdens. Third, the diagnostic codes and clin-
ical classification codes provided by the MPES do not allow
us to further examine the burden of anxiety and depression
on different types of diabetes and/or hypertension. Also, we
could not evaluate the duration and severity of diabetes and
hypertension from MEPS data. Future studies considering
these factors are warranted to confirm our findings. Finally,
the cross-sectional design of our study may limit the ability
to demonstrate causality.
5. Conclusions
In summary, the present study indicated that depression and
anxiety, especially the combination of these two conditions,
are associated with significant impairments in quality of life
and excess economic burden for patients with comorbid dia-
betes and hypertension. The burden estimates can be used as
benchmarks to evaluate future diabetes management pro-
grams. Our findings highlight the needs for timely screening
and early interventions that could help prevent anxiety and/
or depression among adults with comorbid diabetes and
hypertension to reduce their clinical, humanistic, and
economic burden. Furthermore, it is necessary to integrate
mental healthcare into diabetes management to improve
the quality of life for adults with comorbid diabetes and
hypertension. Innovative payment models that encourage
collaboration among primary care providers, diabetes spe-
cialists, and mental health professionals are needed to reduce
healthcare costs for both patients and healthcare payers.
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